<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00334048</url>
  </required_header>
  <id_info>
    <org_study_id>06-036</org_study_id>
    <secondary_id>NYSPI IRB# 5185</secondary_id>
    <nct_id>NCT00334048</nct_id>
  </id_info>
  <brief_title>Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo</brief_title>
  <official_title>Treatment of Sexual Dysfunction Secondary to Antidepressant Pharmacotherapy: A Double-blind Comparison of Requip (Ropinirole) vs. Placebo in Patients Taking SSRI Antidepressants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Luke's-Roosevelt Hospital Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Luke's-Roosevelt Hospital Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antidepressant medicines sometimes cause sexual side effects. The purpose of this study is to&#xD;
      determine whether the sexual dysfunction sometimes caused by selective serotonin reuptake&#xD;
      inhibitor (SSRI) antidepressant medications can be reversed by treatment with Requip&#xD;
      (ropinirole), a medicine which is used to treat Parkinson's Disease and restless leg&#xD;
      syndrome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A significant proportion of patients taking pharmacotherapy for treatment of depression&#xD;
      experience sexual dysfunction at distressing levels, with reported rates varying&#xD;
      considerably. When sexual dysfunction is assessed prospectively using structured&#xD;
      questionnaires, high levels of dysfunction have been found. SSRIs including paroxetine,&#xD;
      sertraline, and other medications, have been shown to have a similar frequency of sexual side&#xD;
      effects and in a recent prospectively designed study 50% of men taking sertraline reported&#xD;
      that they were only &quot;slightly&quot; (18%) or &quot;not at all&quot; (32%) satisfied with their sexual&#xD;
      functioning. It is reported that sexual side effects of antidepressant treatment frequently&#xD;
      result in noncompliance with and/or premature discontinuation of treatment. A recent study&#xD;
      showed that the dopamine agonist Requip (Ropinirole) reduced the amount of SSRI-associated&#xD;
      sexual dysfunction. The proposed study will utilize a placebo control group in a crossover&#xD;
      design to determine the effect on sexual dysfunction of adding Requip (Requip CR formulation)&#xD;
      to the patient's SSRI treatment.&#xD;
&#xD;
      30 patients experiencing sexual dysfunction attributable to SSRI treatment for depression&#xD;
      will be entered into this study. All patients will receive 6 weeks of treatment with&#xD;
      Ropinirole and 6 weeks with placebo in a crossover fashion. Assessments of sexual functioning&#xD;
      and depression will be made at each visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>International Index of Erectile Function (IIEF)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Sexual Function and Satisfaction Questionnaire (SFSQ)</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hamilton Depression Rating Scale, 17 items (HDRS-17)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global Assessment of Functioning Scale (GAFS)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impressions (CGI)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CGI-Sexual functioning (CGI-Sx)</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">9</enrollment>
  <condition>Sexual Dysfunction</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropinirole (Requip)</intervention_name>
    <description>1 mg extended release formulation given once per day to a maximum of 4 per day</description>
    <other_name>requip, ropinirole, requip XL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. male or female outpatients 18-65 years old&#xD;
&#xD;
          2. currently taking fluoxetine, sertraline, paroxetine, citalopram, or escitalopram at a&#xD;
             stable dosage within the ranges specified for 1 month or longer required dosage range:&#xD;
             (Prozac (fluoxetine) 20-80 mg/day; Celexa (citalopram) 20-60 mg/day; Lexapro&#xD;
             (escitalopram) 10-30 mg/day; Zoloft (sertraline) 50-200 mg/day; Paxil (paroxetine)&#xD;
             20-60 mg/day; Paxil CR (paroxetine CR) 25-75 mg/day&#xD;
&#xD;
          3. Currently responding to the SSRI antidepressant treatment, as indicated by&#xD;
&#xD;
               -  a score of 15 or less on the HDRS 24 item at screening and baseline, and (b)&#xD;
                  CGI-Severity score of 2 or less at baseline&#xD;
&#xD;
          4. Meets DSM-IV criteria for Substance-Induced Sexual Dysfunction, with impairment of&#xD;
             desire, arousal, or orgasm&#xD;
&#xD;
          5. Are currently involved in an intimate relationship which includes sexual contact&#xD;
&#xD;
          6. agree to use double-barrier contraception during sexual intercourse during the course&#xD;
             of the study (women only)&#xD;
&#xD;
          7. Agree to the study team contacting the physician who prescribe their SSRI medication&#xD;
             to inform them of their participation in the current study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with a DSM-IV diagnosis of Delirium, Dementia, and Amnestic, and other&#xD;
             Cognitive Disorders,&#xD;
&#xD;
          2. Patients with a principal diagnosis meeting DSM-IV criteria for: Bipolar Disorder or&#xD;
             cyclothymia, Schizophrenia, Delusional (Paranoid) Disorders and Psychotic Disorders&#xD;
             Not Otherwise Specified, or Anorexia Nervosa or Bulimia,&#xD;
&#xD;
          3. Patients who, within the past 6 months, met DSM-IV criteria for abuse of or dependence&#xD;
             on any drug, including alcohol,&#xD;
&#xD;
          4. Patients who would pose a serious risk for suicide during the course of the study, as&#xD;
             evidenced by one of the following:&#xD;
&#xD;
               -  report of having a specific plan for killing themselves,&#xD;
&#xD;
               -  a score of 3 or higher on the Hamilton Depression Rating Scale item 3 as rated by&#xD;
                  the study doctor at the first visit, (indicative of active suicidal thoughts or&#xD;
                  behaviors), or&#xD;
&#xD;
               -  a suicide attempt within the past 6 months,&#xD;
&#xD;
          5. Patients with a history of medical conditions or procedures which may cause sexual&#xD;
             dysfunction, including: peripheral vascular disease, radical prostatectomy,&#xD;
             trans-urethral resection of the prostate [TURP], or spinal cord injury.&#xD;
&#xD;
          6. History of sexual dysfunction predating onset of depression and/or initiation of&#xD;
             antidepressant therapy,&#xD;
&#xD;
          7. Patients receiving any other treatment for sexual dysfunction, including sex therapy&#xD;
&#xD;
          8. Pregnant or nursing women.&#xD;
&#xD;
          9. Patients with unstable or life-threatening medical conditions, such as uncontrolled&#xD;
             hypertension, diabetes, or hypothyroidism, acute infections, pneumonia, severe renal&#xD;
             or hepatic impairment.&#xD;
&#xD;
         10. Patients with any the following: retinal disease, sleep apnea, or narcolepsy.&#xD;
&#xD;
         11. Patients taking dopamine agonist medication.&#xD;
&#xD;
         12. Patients taking medications that are&#xD;
&#xD;
               -  associated with orthostatic hypotension, such as tricyclic antidepressants, MAO&#xD;
                  Inhibitors, and alpha1 antagonists&#xD;
&#xD;
               -  CYP1A2 inhibitors, such as fluoroquinolones, fluvoxamine, cimetidine&#xD;
&#xD;
               -  SSRI medication used cyclically for PMDD&#xD;
&#xD;
         13. Patients who do not expect to have regular sexual contact with another person over the&#xD;
             next 13 weeks.&#xD;
&#xD;
         14. Patients with a DSM-IV diagnosis of Pathological Gambling&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J. Hellerstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Luke's Roosevelt Hospital Center and NY State Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mood Disorders Research Program</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10019</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.depressionny.com</url>
    <description>Mood Disorders Research Program website</description>
  </link>
  <link>
    <url>http://www.columbiapsychiatry.org/research/clinics/mdrp.html</url>
    <description>Columbia Psychiatry website</description>
  </link>
  <reference>
    <citation>Worthington JJ 3rd, Simon NM, Korbly NB, Perlis RH, Pollack MH; Anxiety Disorders Research Program. Ropinirole for antidepressant-induced sexual dysfunction. Int Clin Psychopharmacol. 2002 Nov;17(6):307-10.</citation>
    <PMID>12409684</PMID>
  </reference>
  <reference>
    <citation>Balon R. Sexual function and dysfunction during treatment with psychotropic medications. J Clin Psychiatry. 2005 Nov;66(11):1488-9.</citation>
    <PMID>16420088</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>June 2, 2006</study_first_submitted>
  <study_first_submitted_qc>June 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 6, 2006</study_first_posted>
  <last_update_submitted>February 18, 2015</last_update_submitted>
  <last_update_submitted_qc>February 18, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2015</last_update_posted>
  <responsible_party>
    <name_title>David J. Hellerstein, MD</name_title>
    <organization>NY State Psychiatric Institute</organization>
  </responsible_party>
  <keyword>Medication-induced sexual dysfunction</keyword>
  <keyword>SSRI-induced sexual dysfunction</keyword>
  <keyword>Anorgasmia</keyword>
  <keyword>Delayed ejaculation</keyword>
  <keyword>Sexual dysfunction</keyword>
  <keyword>Antidepressant-induced sexual dysfunction</keyword>
  <keyword>Requip</keyword>
  <keyword>Ropinirole</keyword>
  <keyword>Dopamine agonist</keyword>
  <keyword>Serotonin reuptake inhibitor</keyword>
  <keyword>Sexual dysfunction, physiological, medication-induced</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropinirole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

